Annual Report 2018
Respiratorius presents Annual Report 2018
Lund April 30, 2019d
President Respiratorius AB
+46 709-22 41 40
Respiratorius AB (publ) is developing drug candidates with the goal to launch drugs for common diseases cancer, chronic obstructive pulmonary disease (COPD) and severe asthma. In addition, the project portfolio is a project for improved diagnosis of certain cardiovascular diseases.